

## DAFTAR PUSTAKA

- Abduh, M., Alawiyah, T., Apriansyah, G., Sirodj, R. A., & Afgani, M. W. (2023). Survey Design: Cross Sectional dalam Penelitian Kualitatif. *Jurnal Pendidikan Sains Dan Komputer*, 3(1). <https://doi.org/10.47709/jpsk.v3i01.1955>.
- Alpert, J. S., Thygesen, K., Antman, E., & Bassand, J. P. (2000). Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *Journal of the American College of Cardiology*, 36(3), 959–969. [https://doi.org/10.1016/s0735-1097\(00\)00804-4](https://doi.org/10.1016/s0735-1097(00)00804-4).
- Alquwaizani, M., Buckley, L., Adams, C., & Fanikos, J. (2013). Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. *Current Emergency and Hospital Medicine Reports*, 1(2), 83–97. <https://doi.org/10.1007/s40138-013-0014-6>.
- Alsulaiman, D., Sylvester, K., Stevens, C., & Carter, D. (2016). Comparison of Time to Therapeutic aPTT in Patients Who Received Continuous Unfractionated Heparin After Implementation of Pharmacy-wide Intervention Alerts. *Hospital Pharmacy*, 51(8), 656–661. <https://doi.org/10.1310/hpj5108-656>.
- Aminuddin, A., Cheong, S. S., Roos, N. A. C., & Ugusman, A. (2023). Smoking and Unstable Plaque in Acute Coronary Syndrome: A Systematic Review of The Role of Matrix Metalloproteinases. *International Journal of Medical Sciences*, 20(4), 482–492. <https://doi.org/10.7150/ijms.79889>.
- Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Jr, Ganiats, T. G., Holmes, D. R., Jr, Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., Levine, G. N., Liebson, P. R., Mukherjee, D., Peterson, E. D., Sabatine, M. S., Smalling, R. W., & Zieman, S. J. (2014). 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*, 64(24), e139–e228. <https://doi.org/10.1016/j.jacc.2014.09.017>.
- Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Jr, Chavey, W. E. (2007). ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration

with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *Journal of the American College of Cardiology*, 50(7), e1–e157. <https://doi.org/10.1016/j.jacc.2007.02.013>.

Anggraini, N. A., Faridah Moh Said, Nur Syazana Umar, Rahmania Ambarika, & Reni Nurhidayah. (2023). Social Demographic Factor on Early Detection Ability of Acute Coronary Syndrome in Blitar Regency Indonesia. *Journal Of Nursing Practice*, 6(2), 122–129. <https://doi.org/10.30994/jnp.v6i2.368>.

Antman, E. M., Morrow, D. A., McCabe, C. H., Murphy, S. A., Ruda, M., Sadowski, Z., Budaj, A., López-Sendón, J. L., Guneri, S., Jiang, F., White, H. D., Fox, K. A. A., & Braunwald, E. (2006). Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. *New England Journal of Medicine*, 354(14), 1477–1488. <https://doi.org/10.1056/NEJMoa060898>.

Babes, E. E., Bustea, C., Behl, T., Abdel-Daim, M. M., Nechifor, A. C., Stoicescu, M., Brisc, C. M., Moisi, M., Gitea, D., Iovanovici, D. C., Bungau, A. F., Tit, D. M., & Bungau, S. G. (2022). Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy. *Biomedicine & Pharmacotherapy*, 148, 112772. <https://doi.org/https://doi.org/10.1016/j.biopha.2022.112772>.

Badan Penelitian dan Pengembangan Kesehatan. (2019). *Laporan Riskesdas 2018 Nasional*. Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan.

Badan Pengawas Obat dan Makanan. (2019). *FARMAKOVIGILANS (KEAMANAN OBAT)* (D. Andayani, M. D. Agustin, & R. D. Handari, Eds.). Direktorat Pengawasan Keamanan, Mutu, dan Ekspor Impor Obat, Narkotika, Psikotropika, Prekursor dan Zat Adiktif.

Bakta, I. M. (2007). *Hematologi Klinik Ringkas*, EGC.

Bauer K. A. (2001). Fondaparinux sodium: a selective inhibitor of factor Xa. *American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists*, 58 Suppl 2, S14–S17. [https://doi.org/10.1093/ajhp/58.suppl\\_2.S14](https://doi.org/10.1093/ajhp/58.suppl_2.S14).

Bauer K. A. (2004). Fondaparinux: a new synthetic and selective inhibitor of Factor Xa. *Best practice & research. Clinical haematology*, 17(1), 89–104. <https://doi.org/10.1016/j.beha.2004.03.004>.

- Byrne, R. A., Rossello, X., Coughlan, J. J., et al. (2023). 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). *European Heart Journal*, 44(38), 3720–3826. <https://doi.org/10.1093/eurheartj/ehad191>.
- Canto, J. G., Goldberg, R. J., Hand, M. M., Bonow, R. O., Sopko, G., Pepine, C. J., & Long, T. (2007). Symptom presentation of women with acute coronary syndromes: myth vs reality. *Archives of internal medicine*, 167(22), 2405–2413. <https://doi.org/10.1001/archinte.167.22.2405>.
- Capodanno, D., Bhatt, D. L., Gibson, C. M., James, S., Kimura, T., Mehran, R., ... & Angiolillo, D. J. (2022). Bleeding avoidance strategies in percutaneous coronary intervention. *Nature Reviews Cardiology*, 19(2), 117–132.
- Carey, M. G. (2016). Acute Coronary Syndrome and ST Segment Monitoring. *Critical Care Nursing Clinics of North America*, 28(3), 347–355. <https://doi.org/10.1016/j.cnc.2016.04.006>.
- Cardiac Care Network. (2013). *Management of Acute Coronary Syndrome*. Cardiac Care Network of Ontario.
- Cleveland Clinic. (2022). Antiplatelet Drugs. Diakses dari <https://my.clevelandclinic.org/health/drugs/22955-antiplatelet-drugs>.
- Committee for Proprietary Medical Products. (2000). Points to Consider on The Clinical Investigation of New Medicinal Products for The Treatment of Acute Coronary Syndrome (ACS) Without Persistent ST-Segment Elevation. *European Medicines Agency*.
- Cope, J., Bushwitz, J., Antigua, A., Patel, A., & Zumberg, M. (2013). 758. *Critical Care Medicine*, 41, A188. <https://doi.org/10.1097/01.ccm.0000439996.77733.8b>.
- De Caterina, R., Husted, S., Wallentin, L., et al. (2013). Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. *Thrombosis and haemostasis*, 109(5), 769–786. <https://doi.org/10.1160/TH12-06-0403>.
- de Leon, K., & Winokur, E. J. (2022). Examining Acute Coronary Syndrome Across Ethnicity, Sex, and Age. *The Journal for Nurse Practitioners*, 18(1), 31–35. <https://doi.org/https://doi.org/10.1016/j.nurpra.2021.10.018>.
- Dhungana, S. P., Mahato, A. K., Ghimire, R., & Shreewastav, R. K. (2020). Prevalence of Dyslipidemia in Patients with Acute Coronary Syndrome Admitted at Tertiary Care Hospital in Nepal: A Descriptive Cross-sectional

Study. *JNMA; journal of the Nepal Medical Association*, 58(224), 204–208.  
<https://doi.org/10.31729/jnma.4765>.

DiDomenico, R. J., Dobesh, P. P., Finks, S. W. (2020). *Pharmacotherapy: A Pathophysiologic Approach* (11th ed.). McGraw Hill.

Eikelboom, J. W., Anand, S. S., Malmberg, K., Weitz, J. I., Ginsberg, J. S., & Yusuf, S. (2000). Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. *Lancet (London, England)*, 355(9219), 1936–1942. [https://doi.org/10.1016/S0140-6736\(00\)02324-2](https://doi.org/10.1016/S0140-6736(00)02324-2).

Eikelboom, J. W., & Hirsh, J. (2006). Monitoring unfractionated heparin with the aPTT: time for a fresh look. *Thrombosis and haemostasis*, 96(5), 547–552.

Eikelboom, J. W., & Hirsh, J. (2007). Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. *Journal of thrombosis and haemostasis: JTH*, 5 Suppl 1, 255–263. <https://doi.org/10.1111/j.1538-7836.2007.02499.x>.

Eikelboom, J. W., & Weitz, J. I. (2009). Anticoagulation for ST-Segment Elevation Myocardial Infarction. *Circulation*, 119(9), 1186–1188. <https://doi.org/10.1161/CIRCULATIONAHA.108.845552>.

Falk E. (2000). Multiple culprits in acute coronary syndromes: systemic disease calling for systemic treatment. *Italian heart journal : official journal of the Italian Federation of Cardiology*, 1(12), 835–838.

Fasinu, P. S., & Kustos, S. A. (2020). Anticoagulants. In S. Offermanns & W. Rosenthal (Eds.), *Encyclopedia of Molecular Pharmacology* (pp. 1–10). Springer International Publishing. [https://doi.org/10.1007/978-3-030-21573-6\\_166-1](https://doi.org/10.1007/978-3-030-21573-6_166-1).

Fedan, J. S. (2016). Thrombosis-Embolism☆. In *Reference Module in Biomedical Sciences*. Elsevier. <https://doi.org/https://doi.org/10.1016/B978-0-12-801238-3.99531-X>.

Firouzi, A. (2022). Chapter 25 - Percutaneous Coronary Intervention. In M. Maleki, A. Alizadehasl, & M. Haghjoo (Eds.), *Practical Cardiology (Second Edition)* (Second Edition, pp. 455–461). Elsevier. <https://doi.org/https://doi.org/10.1016/B978-0-323-80915-3.00033-8>.

Funk, D. M. (2012). Coagulation assays and anticoagulant monitoring. *American Society of Hematology*, 460–465. <https://doi.org/10.1182/asheducation.V2012.1.460.3798662>.

Garcia, D. A., Baglin, T. P., Weitz, J. I., & Samama, M. M. (2012). Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th

ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, 141(2, Supplement), e24S-e43S. <https://doi.org/https://doi.org/10.1378/chest.11-2291>.

Gebhard, C. E., Gebhard, C., Maafi, F., Bertrand, M. J., Stähli, B. E., Maredziak, M., Bengs, S., Haider, A., Zhang, Z. W., Smith, D. C., & Ly, H. Q. (2019). Impact of summer season on pre-hospital time delays in women and men undergoing primary percutaneous coronary intervention. *The Science of the total environment*, 656, 322–330. <https://doi.org/10.1016/j.scitotenv.2018.11.363>.

Gillen, C., & Goyal, A. (2024). *Stable Angina*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK559016/>.

Gitt, A. K., Parhofer, K. G., Laufs, U., März, W., Paar, W. D., Bramlage, P., & Marx, N. (2023). Hypercholesterolemia diagnosis, treatment patterns and target achievement in patients with acute coronary syndromes in Germany. *Clinical Research in Cardiology*, 112(2), 299–311. <https://doi.org/10.1007/s00392-022-02108-w>.

Gorennek, B., Blomström Lundqvist, C., Brugada Terradellas, J., et al. (2014). Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. *EP Europace*, 16(11), 1655–1673. <https://doi.org/10.1093/europace/euu208>.

Gupta, J. I., & Shea, M. J. (2023). *Cardiac Auscultation*. <https://www.msdmanuals.com/en-pt/professional/cardiovascular-disorders/approach-to-the-cardiac-patient/cardiac-auscultation>.

GUSTO investigators. (1993). An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *The New England Journal of Medicine*, 329(10), 673–682. <https://doi.org/10.1056/NEJM199309023291001>.

Hapsari, D. C., & Kusharwanti, W. (2014). EFEKTIVITAS DAN KEAMANAN ANTIKOAGULAN PADA SINDROMA KORONER AKUT TANPA ELEVASI SEGMENT. *Jurnal Manajemen Dan Pelayanan Farmasi*, 4(2), 111–116.

Harris, A., & Sutton, G. (1968). Second heart sound in normal subjects. *British heart journal*, 30(6), 739–742. <https://doi.org/10.1136/hrt.30.6.739>.

Hartopo, A. B., Susanti, V. Y., & Setianto, B. Y. (2016). The Prevalence and Impact of Body Mass Index Category in Patients with Acute Myocardial Infarction. *Acta Cardiologia Indonesiana*, 2(2), 61–68.

- Hilman, R. S., Hongcan, Z., Zhexin, S. (2013). Effects of Storage Time and Temperature on Coagulation Tests and Factors in Fresh Plasma. *Biochemical AssaysBiophysical chemistry Preclinic research Proteases*.
- Hirsh, J., Anand, S. S., Halperin, J. L., & Fuster, V. (2001). Mechanism of action and pharmacology of unfractionated heparin. *Arteriosclerosis, thrombosis, and vascular biology*, 21(7), 1094–1096. <https://doi.org/10.1161/hq0701.093686>.
- Hirsh, J., Anand, S. S., Halperin, J. L., & Fuster, V. (2001). Guide to Anticoagulant Therapy: Heparin. *Circulation*, 103(24), 2994–3018. <https://doi.org/10.1161/01.CIR.103.24.2994>.
- Hirsh, J., & Raschke, R. (2004). Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*, 126(3 Suppl), 188S–203S. [https://doi.org/10.1378/chest.126.3\\_suppl.188S](https://doi.org/10.1378/chest.126.3_suppl.188S).
- Ibanez, B., James, S., Agewall, S. et al. (2018). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *European Heart Journal*, 39(2), 119–177. <https://doi.org/10.1093/eurheartj/ehx393>.
- Jacob, R., & Khan, M. (2018). Cardiac Biomarkers: What Is and What Can Be. *Indian Journal of Cardiovascular Disease in Women WINCARS*, 3(4), 240–244. <https://doi.org/10.1055/s-0039-1679104>.
- Jaffer, I. H., & Weitz, J. I. (2018). Chapter 149 - Antithrombotic Drugs. In R. Hoffman, E. J. Benz, L. E. Silberstein, H. E. Heslop, J. I. Weitz, J. Anastasi, M. E. Salama, & S. A. Abutalib (Eds.), *Hematology (Seventh Edition)* (pp. 2168–2188). Elsevier. [https://doi.org/https://doi.org/10.1016/B978-0-323-35762-3.00149-9](https://doi.org/10.1016/B978-0-323-35762-3.00149-9).
- Kaul, S., & Shah, P. K. (2000). Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? *Journal of the American College of Cardiology*, 35(7), 1699–1712. [https://doi.org/https://doi.org/10.1016/S0735-1097\(00\)00648-3](https://doi.org/https://doi.org/10.1016/S0735-1097(00)00648-3).
- Khalid, L., & Dhakam, S. H. (2008). A review of cardiogenic shock in acute myocardial infarction. *Current Cardiology Reviews*, 4(1), 34–40. <https://doi.org/10.2174/157340308783565456>.
- Khan, H. A., Alhomida, A. S., Rammah, T. Y., Sobki, S. H., Ola, M. S., & Khan, A. A. (2013). Alterations in prothrombin time and activated partial thromboplastin time in patients with acute myocardial



infarction. *International journal of clinical and experimental medicine*, 6(4), 294–297.

Khan HA, Alhomida AS, Habib SS, Khan AA, Ola MS, Siddiqui NJ, et al. (2014). Blood carnitine as a biomarker for acute myocardial infarction. *Biomed Res*. 25:63-6.

Konstantinou, K., Tsioufis, C., Koumelli, A., Mantzouranis, M., Kasiakogias, A., Doumas, M., & Tousoulis, D. (2019). Hypertension and patients with acute coronary syndrome: Putting blood pressure levels into perspective. *The Journal of Clinical Hypertension*, 21(8), 1135–1143. <https://doi.org/10.1111/jch.13622>.

Kumar, A., & Cannon, C. P. (2009). Acute coronary syndromes: diagnosis and management, part I. *Mayo Clinic proceedings*, 84(10), 917–938. [https://doi.org/10.1016/S0025-6196\(11\)60509-0](https://doi.org/10.1016/S0025-6196(11)60509-0).

Kusumaningrum, A., & Azinar, M. (2018). Kepesertaan Masyarakat dalam Jaminan Kesehatan Nasional secara Mandiri. *HIGEIA (Journal of Public Health Research and Development)*, 2(1), 149-160. Retrieved from <https://journal.unnes.ac.id/sju/higeia/article/view/17642>.

Lee, J. J. (2015). *Defining Clinical Benefit in Clinical Trials: FDA Perspective*. <https://celiac.org/main/wp-content/uploads/2015/04/great3-07.pdf>.

Lichtman, J. H., Leifheit, E. C., Safdar, B., Bao, H., Krumholz, H. M., Lorenze, N. P., Daneshvar, M., Spertus, J. A., & D'Onofrio, G. (2018). Sex Differences in the Presentation and Perception of Symptoms Among Young Patients With Myocardial Infarction. *Circulation*, 137(8), 781–790. <https://doi.org/10.1161/CIRCULATIONAHA.117.031650>.

Long, D. et al. (2011). *Harrison's Principles Of Internal Medicine*, 18th ed. New York, McGraw-Hill.

Mal, K., Awan, I. D., & Shaukat, F. (2019). Evaluation of Risk Factors Associated with Reinfarction: A Multicenter Observational Study. *Cureus*, 11(11), e6063. <https://doi.org/10.7759/cureus.6063>.

Malik, T. F., Tivakaran, V. S. (2023). Percutaneous Transluminal Coronary Angioplasty. In StatPearls [Internet]. Diakses dari <https://www.ncbi.nlm.nih.gov/books/NBK535417/>.

Marenzi, G., Cabiati, A., & Assanelli, E. (2012). Chronic kidney disease in acute coronary syndromes. *World Journal of Nephrology*, 1(5), 134–145. <https://doi.org/10.5527/wjn.v1.i5.134>.

- Marenzi, G., Cabiati, A., Bertoli, S. V., Assanelli, E., Marana, I., De Metrio, M., Rubino, M., Moltrasio, M., Grazi, M., Campodonico, J., Milazzo, V., Veglia, F., Lauri, G., & Bartorelli, A. L. (2013). Incidence and relevance of acute kidney injury in patients hospitalized with acute coronary syndromes. *The American journal of cardiology*, 111(6), 816–822. <https://doi.org/10.1016/j.amjcard.2012.11.046>.
- Mehta, S. R. (2008). Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes. *European Heart Journal Supplements*, 10(suppl\_C), C14–C21. <https://doi.org/10.1093/eurheartj/sun002>.
- Mehta, S. R., Boden, W. E., Eikelboom, J. W., Flather, M., Steg, P. G., Avezum, A., Afzal, R., Piegas, L. S., Faxon, D. P., Widimsky, P., Budaj, A., Chrolavicius, S., Rupprecht, H.-J., Jolly, S., Granger, C. B., Fox, K. A. A., Bassand, J.-P., & Yusuf, S. (2008). Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes. *Circulation*, 118(20), 2038–2046. <https://doi.org/10.1161/CIRCULATIONAHA.108.789479>.
- Meyer, M. R., Bernheim, A. M., Kurz, D. J., O'Sullivan, C. J., Tüller, D., Zbinden, R., Rosemann, T., & Eberli, F. R. (2019). Gender differences in patient and system delay for primary percutaneous coronary intervention: current trends in a Swiss ST-segment elevation myocardial infarction population. *European heart journal. Acute cardiovascular care*, 8(3), 283–290. <https://doi.org/10.1177/2048872618810410>.
- Namiuchi, S., Sunamura, S., Tanita, A., Ushigome, R., Noda, K., & Takii, T. (2021). Higher Recurrence Rate of Acute Coronary Syndrome in Patients with Multiple-Time Myocardial Infarction. *International heart journal*, 62(3), 493–498. <https://doi.org/10.1536/ihj.20-546>.
- National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Fondaparinux. Dalam LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD). Tersedia dari: <https://www.ncbi.nlm.nih.gov/books/NBK548551/>.
- Nutescu, E. A., Burnett, A., Fanikos, J., Spinler, S., & Wittkowsky, A. (2016). Pharmacology of anticoagulants used in the treatment of venous thromboembolism. *Journal of Thrombosis and Thrombolysis*, 41(1), 15–31. <https://doi.org/10.1007/s11239-015-1314-3>.
- Oduah, E. I., Linhardt, R. J., & Sharfstein, S. T. (2016). Heparin: Past, Present, and Future. *Pharmaceuticals (Basel, Switzerland)*, 9(3), 38. <https://doi.org/10.3390/ph9030038>.



- Ojha, N., & Dhamoon, A. S. (2023). Myocardial Infarction. Dalam StatPearls [Internet]. Diakses dari <https://www.ncbi.nlm.nih.gov/books/NBK537076/>.
- Onwordi, E. N., Gamal, A., & Zaman, A. (2018). Anticoagulant Therapy for Acute Coronary Syndromes. *Interventional cardiology (London, England)*, 13(2), 87–92. <https://doi.org/10.15420/icr.2017:26:1>.
- Ooi, D. S., Isotalo, P. A., & Veinot, J. P. (2000). Correlation of antemortem serum creatine kinase, creatine kinase-MB, troponin I, and troponin T with cardiac pathology. *Clinical chemistry*, 46(3), 338–344.
- Pascual, I., Hernandez-Vaquero, D., Almendarez, M., Lorca, R., Escalera, A., Díaz, R., Alperi, A., Carnero, M., Silva, J., Morís, C., & Avanzas, P. (2020). Observed and Expected Survival in Men and Women after Suffering a STEMI. *Journal of Clinical Medicine*, 9(4), 1174. <https://doi.org/10.3390/jcm9041174>.
- Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. (2018). Pedoman Tata Laksana Sindrom Koroner Akut. In *Jurnal Kardiologi Indonesia* (4th ed.).
- Picariello, C., Lazzeri, C., Attanà, P., Chiostri, M., Gensini, G. F., & Valente, S. (2011). The impact of hypertension on patients with acute coronary syndromes. *International Journal of Hypertension*, 2011, 563657. <https://doi.org/10.4061/2011/563657>.
- Reed, M., Kerndt, C. C., & Nicolas, D. (2023). Alteplase. In StatPearls [Internet]. Diakses dari <https://www.ncbi.nlm.nih.gov/books/NBK499977/>.
- Rogers, D., Campbell, R., Catha, G., Patterson, K., & Puccio, D. (2022). *Acute Coronary Syndrome*. American Heart Association. <https://www.heart.org/en/health-topics/heart-attack/about-heart-attacks/acute-coronary-syndrome>.
- Sami, S., & Willerson, J. T. (2010). Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2). *Texas Heart Institute journal*, 37(3), 262–275.
- Samsu N, Sargowo D. (2007). Sensitivitas dan spesifisitas troponin I dan T pada diagnosis infark miokard akut. *Majalah Kedokteran Indonesia*. 57(10):363-72.
- Sastroasmoro, Sudigdo & Ismael, Sofyan. (2014). *Dasar – Dasar Metodologi Penelitian Klinis Edisi ke-5*. Sagung Seto. Jakarta.
- Sharma, T., Mehta, P., & Gajra, A. (2010). Update on fondaparinux: role in management of thromboembolic and acute coronary events. *Cardiovascular*

& hematological agents in medicinal chemistry, 8(2), 96–103.  
<https://doi.org/10.2174/187152510791170933>.

Shimokawa, H., & Yasuda, S. (2008). Myocardial ischemia: Current concepts and future perspectives. *Journal of Cardiology*, 52(2), 67–78.  
<https://doi.org/10.1016/j.jjcc.2008.07.016>.

Silvain, J., Beygui, F., Barthélémy, O., Pollack, C., Jr, Cohen, M., Zeymer, U., Huber, K., Goldstein, P., Cayla, G., Collet, J. P., Vicaut, E., & Montalescot, G. (2012). Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. *BMJ (Clinical research ed.)*, 344, e553.  
<https://doi.org/10.1136/bmj.e553>.

Simonsson, M., Wallentin, L., Alfredsson, J., Erlinge, D., Hellström Ångerud, K., Hofmann, R., ... & Jernberg, T. (2020). Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDEHEART registry. *European heart journal*, 41(7), 833–843.

Singh, D., Gupta, K., dan Vacek, J.L., (2014). Anticoagulation and Antiplatelet Therapy in Acute Coronary Syndromes. *Cleveland Clinic Journal of Medicine*, 81: 103–114.

Spinler, S. A., Inverso, S. M., Cohen, M., Goodman, S. G., Stringer, K. A., Antman, E. M., & ESSENCE and TIMI 11B Investigators (2003). Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. *American heart journal*, 146(1), 33–41.  
[https://doi.org/10.1016/S0002-8703\(03\)00121-2](https://doi.org/10.1016/S0002-8703(03)00121-2).

Sposato, L. A., Hilz, M. J., Aspberg, S., Murthy, S. B., Bahit, M. C., Hsieh, C. Y., Sheppard, M. N., Scheitz, J. F., & World Stroke Organisation Brain & Heart Task Force (2020). Post-Stroke Cardiovascular Complications and Neurogenic Cardiac Injury: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, 76(23), 2768–2785.  
<https://doi.org/10.1016/j.jacc.2020.10.009>.

Stringer, J.L. (2009). *Konsep Dasar Farmakologi: Panduan Untuk Mahasiswa*. 3rd ed. Malang: EGC.

Sugiyono. (2014). *Metode Penelitian Pendidikan Pendekatan Kuantitatif, Kualitatif, dan R&D*. Bandung: Alfabeta.

Susilo, C. (2015). Identifikasi Faktor Usia, Jenis Kelamin dengan Luas Infark Miokard Pada Penyakit Jantung Koroner (PJK) di Ruang ICCU RSD DR. Soebandi Jember, *The Indonesian Journal Of Health Science*; Vol.6(1): 1-7.

- Svendsten, K., Krogh, H. W., Igland, J., Tell, G. S., Mundal, L. J., Holven, K. B., Bogsrud, M. P., Leren, T. P., & Retterstøl, K. (2021). 2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia. *Atherosclerosis*, 319, 28–34. <https://doi.org/10.1016/j.atherosclerosis.2020.12.019>.
- Sweis, R. N., & Jivan, A. (2024). *Complications of Acute Coronary Syndromes*. Northwestern University Feinberg School of Medicine. Reviewed/Revised February 2024.
- Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., & White, H. D. (2018). Fourth Universal Definition of Myocardial Infarction (2018). *Circulation*, 138(20). <https://doi.org/10.1161/CIR.0000000000000617>.
- Triwibowo, C. (2013). *Manajemen Pelayanan Keperawatan di Rumah Sakit*. Jakarta.
- Turpie, A. G., Bauer, K. A., Eriksson, B. I., & Lassen, M. R. (2002). Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. *Archives of internal medicine*, 162(16), 1833–1840. <https://doi.org/10.1001/archinte.162.16.1833>.
- Turpie A. G. (2006). Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. *Vascular health and risk management*, 2(4), 371–378. <https://doi.org/10.2147/vhrm.2006.2.4.371>.
- Virani, S. S., Alonso, A., Aparicio, H. J., et al. (2021). Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. *Circulation*, 143(8), e254–e743. <https://doi.org/10.1161/CIR.0000000000000950>.
- Wan, Azman. (2017). Annual Report of the NCVD-ACS Registry, 2014 - 2015. Kuala Lumpur, Malaysia: National Heart Association of Malaysia (NHAM) 2017. <https://www.malaysianheart.org/files/5d1998d5b6248.pdf>.
- Warnock, L. B. & Huang, D. (2023). *Heparin* In StatPearls [Internet]. <https://www.ncbi.nlm.nih.gov/books/NBK559016/>.
- Warren, A., & Nunn, M. (2020). Acute coronary syndrome: risk factors, diagnosis and treatment. *Pharmaceutical Journal*.
- Weerasaksanti, A., Siwamogsatham, S., Kunlomas, Y., & Bunditanukul, K. (2023). Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome. *BMC cardiovascular disorders*, 23(1), 243. <https://doi.org/10.1186/s12872-023-03278-9>.

- White, C.M. (2021). Why Prescription Drugs Can Work Differently for Different People. UCONN. <https://today.uconn.edu/2021/10/why-prescription-drugs-can-work-differently-for-different-people-2/#>.
- Wimmer, S., Neubert, A., & Rascher, W. (2015). The Safety of Drug Therapy in Children. *Deutsches Arzteblatt International*, 112(46), 781–787. <https://doi.org/10.3238/arztebl.2015.0781>.
- Winda, S. (2018). Formularium Nasional (FORNAS) dan *e-Catalogue* Obat Sebagai Upaya Pencegahan Korupsi dalam Tata Kelola Obat Jaminan Kesehatan Nasional (JKN). *Integritas: Jurnal Antikorrupsi*, 4(2), 177-206.
- Wolk, R., Berger, P., Lennon, R. J., Brilakis, E. S., & Somers, V. K. (2003). Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. *Circulation*, 108(18), 2206–2211. <https://doi.org/10.1161/01.CIR.0000095270.85646.E8>.
- World Health Organization. (2020). *The top 10 causes of death*. World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>.
- Xiao, Z. M., Rosenthal, N., Kartashov, A., Levorsen, A., & Shah, B. (2019). P6425 Comparative effectiveness and costs of enoxaparin versus unfractionated heparin in treating acute coronary syndrome. *European Heart Journal*, 40(Supplement\_1), ehz746.1019. <https://doi.org/10.1093/eurheartj/ehz746.1019>.
- Yan, Y., Gong, W., Ma, C., Wang, X., & Smith, S. C. (2022). Postprocedure Anticoagulation in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *J Am Coll Cardiol Interv*, 15(3), 251–263.
- Yudi, M. B., Clark, D. J., Farouque, O., et al. (2019). Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention. *American heart journal*, 212, 134–143. <https://doi.org/10.1016/j.ahj.2019.02.013>.
- Yusuf, S., Mehta, S.R., Chrolavicius, S., Afzal, R., Pogue, J., Granger, C.B., et al. (2006). Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. *The New England Journal of Medicine*, 354: 1464–1476.
- Yusuf, S., Mehta, S. R., Chrolavicius, S., Afzal, R., Pogue, J., Granger, C. B., Budaj, A., Peters, R. J., Bassand, J. P., Wallentin, L., Joyner, C., Fox, K. A., & OASIS-6 Trial Group (2006). Effects of fondaparinux on mortality and

reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. *JAMA*, 295(13), 1519–1530. <https://doi.org/10.1001/jama.295.13.joc60038>.

Zuhdi, A. S., Mariapun, J., Mohd Hairi, N. N., Wan Ahmad, W. A., Abidin, I. Z., Undok, A. W., Ismail, M. D., & Sim, K. H. (2013). Young coronary artery disease in patients undergoing percutaneous coronary intervention. *Annals of Saudi medicine*, 33(6), 572–578. <https://doi.org/10.5144/0256-4947.2013.572>.